Siltuximab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and HAS (France) recommended or restricted siltuximab, while AWMSG (Wales) did not recommend it.
Assessment has run over 6.9 years, from 25 Sep 2014 at AWMSG (Wales) to 24 Aug 2021 at AOTMIT (Poland).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2021, after a resubmission.
No assessment is on file from SMC (Scotland), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess siltuximab, on 25 Sep 2014; AOTMIT (Poland) did not open a file until 24 Aug 2021 — a wide spread of 6.9 years between the earliest and latest system to look at it.
2 of the 6 agencies here assessed siltuximab more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for siltuximab.
The full ledger for siltuximab reads 4 recommended, 2 not recommended, 1 advice and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 24 Aug 2021 | programu lekowego „Leczenie idiopatycznej wieloogniskowej choroby Castlemana (ICD-10 D47.Z2) | recommended | source |
| PBAC (Australia) | 2021 | Idiopathic multicentric Castleman’s disease (iMCD) | Not Recommended | source |
| HAS (France) | 16 Sep 2020 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
| PHARMAC (New Zealand) | 11 May 2016 | HHV-8 negative Multicentric Castleman's disease | funding application decided · decision reached | source |
| G-BA (Germany) | 4 Dec 2014 | Sylvant — benefit assessment §35a | added benefit: non-quantifiable | source |
3 further decisions for siltuximab, across 3 agencies, are not shown here. They link to 1 further source document.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 8 decisions for siltuximab from 6 agencies, 2014 to 2021. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.